| 摘要 |
FIELD: medicine, urology. SUBSTANCE: invention proposes to use immunomodulating agent lycopide depending on the parent activity of cells of neutrophile-leukocyte order. In increase of activity in lymphocytic order: CD 25+ > 16, CD 71+ > 4, HLA-DR > 30; in monocytic order: CD 25+ > 30, CD 71+ > 35, HLA-DR > 70 and in neutrophile order: HCT > 28 and HCT3 > 38 lycopide is prescribed in the dose 10 mg by sublingual route every day before eating in course dose 1 g in combination with prescription of macrolide order antibiotics in therapeutic doses. In reduction of activity in lymphocytic order: CD 25+ <10, CD 71+ <1, HLA-DR <19; in monocytic order: CD 25+ <20, CD 71+ <30, HLA- DR <60 and in neutrophile order: HCT <17 and HCT3 <27 lycopide is prescribed in the dose 10 mg by sublingual route every day before eating in course dose 1 g and intake of macrolide antibiotics in therapeutic doses is prescribed beginning from 5-th day of lycopide treatment onset. Method allows to reduce treatment period and diminish course dose of antibiotics. Invention can be used for treatment of chronic chlamydiosis prostatitis resistant to conventional therapy. EFFECT: improved method and enhanced effectiveness of treatment. 4 tbl, 2 ex
|
